{"success":true,"data":{"pressRelease":{"id":"153318","rtpr_id":"nGNX4Mqbn3-20260925","ticker":"HIMS","exchange":"NYSE","all_tickers":["HIMS"],"title":"HIMS Stockholders Have Rights – If You Lost Money Investing in Hims & Hers Health, Inc. Contact Robbins LLP for Information About Recovering Your Losses","author":"Globe Newswire","published_at":"2026-09-25T18:10:44.104Z","article_body":"SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm\nRobbins LLP\n(https://www.globenewswire.com/Tracker?data=-FPxWb-BvFEKGsfn4j7BaS4nAkHM8xz7aF2ldnC3hIukW8b3Mmg6CZR8rBtZvMPGzpNp9n8Lko1IAk_yHdnnc2sgeKM5zBOd9l_PQJ3a6MA=) reminds\ninvestors that a class action was filed on behalf of all persons and entities\nwho purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS)\nsecurities between August 4, 2025 and July 29, 2026, inclusive (the \"Class\nPeriod\"). Hims operates a health and wellness platform that connects consumers\nto licensed healthcare professionals.\n\nThe complaint alleges that Hims & Hers shared customers' protected health\ninformation with advertising platforms and engaged in other deceptive\nadvertising practices.\n\nInvestors who suffered significant losses during the Class Period may be\neligible to participate in the lawsuit and should contact\n(https://www.globenewswire.com/Tracker?data=eQJz9Z_yvvLAHwjm7GBojDmL-xtBb0d_wU1wAt3ognb97B3_qLB6P6weyR9QQfbiZL8Bf6ZQfWbDQCB9CzCBZVqT6TQLOWc-lIo8jVyzZ-s=)\nRobbins LLP for information prior to the November 2, 2026, lead plaintiff\ndeadline.\n\nListen to our podcast\n(https://www.globenewswire.com/Tracker?data=6NZwpHT_pQ0BW2ziBvd2NK7Siw2GBEk4DGIhZgEqZkGUFD-ofdDL8ljuW8jcT9f29mtxygCZoL4KjVW3oj_--wDHrbxFn4CMwSzVlPVVZBc=).\n\nWhy Was Hims & Hers Sued?\n\nAccording to the complaint, defendants failed to disclose to investors that:\n\n(1) the Company shared consumers’ health information with third-party\nadvertising platforms; (2) the Company charges consumers for prescriptions\nalmost immediately after they submit an intake form, despite telling consumers\nthat they will be able to consult with a medical provider to find a treatment\nthat is “right for them;” \n(3) the foregoing conduct subjected the Company to regulatory scrutiny; \n(4) as a result, the Company was reasonably likely to incur fees and\npenalties; and \n(5) as a result of the foregoing, defendants’ positive statements about the\nCompany’s business,\n\noperations, and prospects were materially misleading and/or lacked a\nreasonable basis.\n\nWhy Did HIMS Stock Drop?\n\nPlaintiff alleges that on July 29, 2026, during market hours, the Federal\nTrade Commission (“FTC”) announced it had filed a lawsuit against Hims\n“alleging that the telehealth provider shared consumers’ sensitive health\ninformation about medical conditions with third-party advertising platforms\ndespite claiming its services maintain consumers’ privacy and deceives users\nabout its billing and cancellation practices.”\n\nAccording to the FTC’s complaint, Hims engages in other deceptive\nadvertising practices, including failing to “clearly disclose that it\ncharges consumers for prescriptions almost immediately after they submit an\nintake form, despite telling consumers that they will be able to consult with\na medical provider to find a treatment that is ‘right for them.’” The\ncomplaint further alleges that, contrary to its promises that the platform is\n“100% online, private, and secure,” Hims “shared sensitive health\ninformation with third-party advertising companies and\nplatforms . . . such as Meta Platforms, Inc. (‘Meta’) and Snap Inc.\n(‘Snap’).”\n\nOn this news, shares of Hims declined $4.32, or 14.73%, to close at $25.00 on\nJuly 29, 2026.\n\nWho May Be Eligible to Participate in the Hims & Hers Class Action?\n\nThe lawsuit seeks to represent investors who purchased or otherwise acquired\nHims securities between 4, 2025 and July 29, 2026.   Investors who suffered\nlosses during that period may have legal rights under the federal securities\nlaws.\n\nWhat Is a Lead Plaintiff?\n\nThe lead plaintiff is a court-appointed investor who represents the interests\nof all class members throughout the litigation. Shareholders who wish to lead\nthe case should contact Robbins LLP prior to the November 2, 2026, lead\nplaintiff deadline.\n\nServing as lead plaintiff is not required to share in any potential recovery.\nInvestors who do not seek appointment may remain absent class members if the\ncase proceeds and later resolves successfully.\n\nDoes It Cost Anything to Participate?\n\nNo. Robbins LLP represents investors on a contingency fee basis.\n\nWhy Robbins LLP?\n\nA recognized leader in shareholder rights litigation, Robbins LLP\n(https://www.globenewswire.com/Tracker?data=-FPxWb-BvFEKGsfn4j7BacO1NG89uCERJzWpnxu82yhKOaCqTMxaZPHGYoB_2k6wFuMRYMZpcXDt3RzFNyuQdA==)\nhas helped restore more than $2 billion in value to shareholders and secured\nsome of the largest recoveries in shareholder derivative litigation history.\n\n\"Companies have an obligation to provide investors with complete and accurate\ninformation so that markets can function fairly and efficiently,\" said Brian\nJ. Robbins, Founding Partner of Robbins LLP.\n\nTo be notified if a class action against Hims & Hers Health, Inc. settles or\nto receive free alerts when corporate executives engage in wrongdoing, sign up\nfor Stock Watch\n(https://www.globenewswire.com/Tracker?data=QiiQpFIaXeuHiflattcOl41uXXdZ6ynlo6J2x8SyTYxmRh_C_4sqGBMZ7x1G5WXadcw6c7Kzh36uK6OmMiq5qcdpR8zBW_72dFihY-fRHww=) today.\n\nContact Robbins LLP\n\nInvestors seeking additional information about the Hims & Hers Health, Inc.\nsecurities class action may contact Robbins LLP by submitting\n(https://www.globenewswire.com/Tracker?data=DFsQLG7i-zVKyljmJOCBhWdGJI5sNOWgMicDJdVq5_oRIM3SLcYnUoh7jU-3Jp3yZftnImTRI2ASOoUOhOwwPsgV9juu69VO6aC3CYC5rAQ=)\nan inquiry, emailing\n(https://www.globenewswire.com/Tracker?data=12F_qFaCx9lyGhr1vzmBWNg3NtDTG_2b5R-WChJuXcqFt9iE4WTzEpIuEf9XQFc4JhcEo4qfgIwzUoKBUPUGkA==)\nattorney Aaron Dumas, Jr., or calling (800) 350-6003.\n\nAttorney Advertising. Past results do not guarantee a similar outcome.\n\n Contact: Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com  https://www.facebook.com/RobbinsLLP/ https://www.linkedin.com/company/robbins-llp/  \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f6c754ad-b344-4389-a551-cf97ce05752e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4Mqbn3-20260925","title":"HIMS Stockholders Have Rights – If You Lost Money Investing in Hims & Hers Health, Inc. Contact Robbins LLP for Information About Recovering Your Losses","author":"Globe Newswire","ticker":"HIMS","created":"2026-09-25T18:10:44.104Z","tickers":["HIMS"],"exchange":"NYSE","article_body":"SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm\nRobbins LLP\n(https://www.globenewswire.com/Tracker?data=-FPxWb-BvFEKGsfn4j7BaS4nAkHM8xz7aF2ldnC3hIukW8b3Mmg6CZR8rBtZvMPGzpNp9n8Lko1IAk_yHdnnc2sgeKM5zBOd9l_PQJ3a6MA=) reminds\ninvestors that a class action was filed on behalf of all persons and entities\nwho purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS)\nsecurities between August 4, 2025 and July 29, 2026, inclusive (the \"Class\nPeriod\"). Hims operates a health and wellness platform that connects consumers\nto licensed healthcare professionals.\n\nThe complaint alleges that Hims & Hers shared customers' protected health\ninformation with advertising platforms and engaged in other deceptive\nadvertising practices.\n\nInvestors who suffered significant losses during the Class Period may be\neligible to participate in the lawsuit and should contact\n(https://www.globenewswire.com/Tracker?data=eQJz9Z_yvvLAHwjm7GBojDmL-xtBb0d_wU1wAt3ognb97B3_qLB6P6weyR9QQfbiZL8Bf6ZQfWbDQCB9CzCBZVqT6TQLOWc-lIo8jVyzZ-s=)\nRobbins LLP for information prior to the November 2, 2026, lead plaintiff\ndeadline.\n\nListen to our podcast\n(https://www.globenewswire.com/Tracker?data=6NZwpHT_pQ0BW2ziBvd2NK7Siw2GBEk4DGIhZgEqZkGUFD-ofdDL8ljuW8jcT9f29mtxygCZoL4KjVW3oj_--wDHrbxFn4CMwSzVlPVVZBc=).\n\nWhy Was Hims & Hers Sued?\n\nAccording to the complaint, defendants failed to disclose to investors that:\n\n(1) the Company shared consumers’ health information with third-party\nadvertising platforms; (2) the Company charges consumers for prescriptions\nalmost immediately after they submit an intake form, despite telling consumers\nthat they will be able to consult with a medical provider to find a treatment\nthat is “right for them;” \n(3) the foregoing conduct subjected the Company to regulatory scrutiny; \n(4) as a result, the Company was reasonably likely to incur fees and\npenalties; and \n(5) as a result of the foregoing, defendants’ positive statements about the\nCompany’s business,\n\noperations, and prospects were materially misleading and/or lacked a\nreasonable basis.\n\nWhy Did HIMS Stock Drop?\n\nPlaintiff alleges that on July 29, 2026, during market hours, the Federal\nTrade Commission (“FTC”) announced it had filed a lawsuit against Hims\n“alleging that the telehealth provider shared consumers’ sensitive health\ninformation about medical conditions with third-party advertising platforms\ndespite claiming its services maintain consumers’ privacy and deceives users\nabout its billing and cancellation practices.”\n\nAccording to the FTC’s complaint, Hims engages in other deceptive\nadvertising practices, including failing to “clearly disclose that it\ncharges consumers for prescriptions almost immediately after they submit an\nintake form, despite telling consumers that they will be able to consult with\na medical provider to find a treatment that is ‘right for them.’” The\ncomplaint further alleges that, contrary to its promises that the platform is\n“100% online, private, and secure,” Hims “shared sensitive health\ninformation with third-party advertising companies and\nplatforms . . . such as Meta Platforms, Inc. (‘Meta’) and Snap Inc.\n(‘Snap’).”\n\nOn this news, shares of Hims declined $4.32, or 14.73%, to close at $25.00 on\nJuly 29, 2026.\n\nWho May Be Eligible to Participate in the Hims & Hers Class Action?\n\nThe lawsuit seeks to represent investors who purchased or otherwise acquired\nHims securities between 4, 2025 and July 29, 2026.   Investors who suffered\nlosses during that period may have legal rights under the federal securities\nlaws.\n\nWhat Is a Lead Plaintiff?\n\nThe lead plaintiff is a court-appointed investor who represents the interests\nof all class members throughout the litigation. Shareholders who wish to lead\nthe case should contact Robbins LLP prior to the November 2, 2026, lead\nplaintiff deadline.\n\nServing as lead plaintiff is not required to share in any potential recovery.\nInvestors who do not seek appointment may remain absent class members if the\ncase proceeds and later resolves successfully.\n\nDoes It Cost Anything to Participate?\n\nNo. Robbins LLP represents investors on a contingency fee basis.\n\nWhy Robbins LLP?\n\nA recognized leader in shareholder rights litigation, Robbins LLP\n(https://www.globenewswire.com/Tracker?data=-FPxWb-BvFEKGsfn4j7BacO1NG89uCERJzWpnxu82yhKOaCqTMxaZPHGYoB_2k6wFuMRYMZpcXDt3RzFNyuQdA==)\nhas helped restore more than $2 billion in value to shareholders and secured\nsome of the largest recoveries in shareholder derivative litigation history.\n\n\"Companies have an obligation to provide investors with complete and accurate\ninformation so that markets can function fairly and efficiently,\" said Brian\nJ. Robbins, Founding Partner of Robbins LLP.\n\nTo be notified if a class action against Hims & Hers Health, Inc. settles or\nto receive free alerts when corporate executives engage in wrongdoing, sign up\nfor Stock Watch\n(https://www.globenewswire.com/Tracker?data=QiiQpFIaXeuHiflattcOl41uXXdZ6ynlo6J2x8SyTYxmRh_C_4sqGBMZ7x1G5WXadcw6c7Kzh36uK6OmMiq5qcdpR8zBW_72dFihY-fRHww=) today.\n\nContact Robbins LLP\n\nInvestors seeking additional information about the Hims & Hers Health, Inc.\nsecurities class action may contact Robbins LLP by submitting\n(https://www.globenewswire.com/Tracker?data=DFsQLG7i-zVKyljmJOCBhWdGJI5sNOWgMicDJdVq5_oRIM3SLcYnUoh7jU-3Jp3yZftnImTRI2ASOoUOhOwwPsgV9juu69VO6aC3CYC5rAQ=)\nan inquiry, emailing\n(https://www.globenewswire.com/Tracker?data=12F_qFaCx9lyGhr1vzmBWNg3NtDTG_2b5R-WChJuXcqFt9iE4WTzEpIuEf9XQFc4JhcEo4qfgIwzUoKBUPUGkA==)\nattorney Aaron Dumas, Jr., or calling (800) 350-6003.\n\nAttorney Advertising. Past results do not guarantee a similar outcome.\n\n Contact: Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com  https://www.facebook.com/RobbinsLLP/ https://www.linkedin.com/company/robbins-llp/  \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f6c754ad-b344-4389-a551-cf97ce05752e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-25T18:10:44.154542241Z","server_sent_at_ms":1790359844154},"received_at":"2026-09-25T18:10:44.206Z","source_url":null},"analysis":{"id":"142120","press_release_id":"153318","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["FTC lawsuit alleging sharing of consumers' protected health information with Meta and Snap","alleged deceptive billing: consumers charged for prescriptions almost immediately after intake form submission","ongoing regulatory scrutiny raises risk of fees and penalties"],"eventType":"legal_litigation","narrative":"Robbins LLP announced a securities class action against Hims & Hers covering investors who purchased HIMS securities between August 4, 2025 and July 29, 2026, with a November 2, 2026 lead plaintiff deadline.\n\nThe suit follows an FTC complaint alleging HIMS shared consumers' sensitive health information with advertising platforms including Meta and Snap and used deceptive billing and cancellation practices.\n\nThe release notes HIMS shares fell $4.32, or 14.73%, to $25.00 on July 29, 2026 when the FTC action was announced; this release itself is law-firm solicitation, not a new company disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm class-action solicitation following previously disclosed FTC suit -- suppress as standalone news."},"keyFigures":{"customDimensions":{"stock_drop_pct":"14.73%","stock_drop_usd":"$4.32","class_period_end":"July 29, 2026","class_period_start":"August 4, 2025","close_price_on_drop":"$25.00","lead_plaintiff_deadline":"November 2, 2026"}},"quotedText":"shares of Hims declined $4.32, or 14.73%, to close at $25.00 on July 29, 2026.","namedEntities":{"people":[{"name":"Brian J. Robbins","role":"Founding Partner, Robbins LLP"},{"name":"Aaron Dumas, Jr.","role":"attorney contact, Robbins LLP"}],"products":[],"companies":[{"name":"Hims & Hers Health, Inc.","ticker":"HIMS","relationship":"defendant/issuer"},{"name":"Robbins LLP","relationship":"plaintiff law firm"},{"name":"Federal Trade Commission (FTC)","relationship":"regulator/plaintiff in underlying suit"},{"name":"Meta Platforms, Inc.","ticker":"META","relationship":"alleged recipient of shared health data"},{"name":"Snap Inc.","ticker":"SNAP","relationship":"alleged recipient of shared health data"}],"dollarAmounts":[{"amount":"$2 billion","context":"value Robbins LLP claims to have restored to shareholders historically"},{"amount":"$4.32","context":"HIMS share price decline on July 29, 2026"},{"amount":"$25.00","context":"HIMS closing price on July 29, 2026"}]},"materialImpact":{"score":2,"reasoning":"Plaintiff law-firm solicitation by Robbins LLP rather than issuer disclosure. The underlying FTC lawsuit and 14.73% one-day stock drop were previously disclosed events; this release adds only class-action solicitation and a lead plaintiff deadline."},"tickerRelevance":{"others":[{"ticker":"META","relevance":"mentioned"},{"ticker":"SNAP","relevance":"mentioned"}],"primary":"HIMS"},"globalImportance":18,"audienceRelevance":35,"eventTypeSecondary":["regulatory"],"importanceComponents":{"tickerTier":"mid-cap retail-favorite","eventGravity":"law-firm-solicitation","issuerAuthored":false,"retailFavoriteBoost":true}},"event_type":"legal_litigation","event_type_secondary":["regulatory"],"sentiment":"neutral","material_impact_score":2,"narrative":"Robbins LLP announced a securities class action against Hims & Hers covering investors who purchased HIMS securities between August 4, 2025 and July 29, 2026, with a November 2, 2026 lead plaintiff deadline.\n\nThe suit follows an FTC complaint alleging HIMS shared consumers' sensitive health information with advertising platforms including Meta and Snap and used deceptive billing and cancellation practices.\n\nThe release notes HIMS shares fell $4.32, or 14.73%, to $25.00 on July 29, 2026 when the FTC action was announced; this release itself is law-firm solicitation, not a new company disclosure.","key_figures":{"customDimensions":{"stock_drop_pct":"14.73%","stock_drop_usd":"$4.32","class_period_end":"July 29, 2026","class_period_start":"August 4, 2025","close_price_on_drop":"$25.00","lead_plaintiff_deadline":"November 2, 2026"}},"named_entities":{"people":[{"name":"Brian J. Robbins","role":"Founding Partner, Robbins LLP"},{"name":"Aaron Dumas, Jr.","role":"attorney contact, Robbins LLP"}],"products":[],"companies":[{"name":"Hims & Hers Health, Inc.","ticker":"HIMS","relationship":"defendant/issuer"},{"name":"Robbins LLP","relationship":"plaintiff law firm"},{"name":"Federal Trade Commission (FTC)","relationship":"regulator/plaintiff in underlying suit"},{"name":"Meta Platforms, Inc.","ticker":"META","relationship":"alleged recipient of shared health data"},{"name":"Snap Inc.","ticker":"SNAP","relationship":"alleged recipient of shared health data"}],"dollarAmounts":[{"amount":"$2 billion","context":"value Robbins LLP claims to have restored to shareholders historically"},{"amount":"$4.32","context":"HIMS share price decline on July 29, 2026"},{"amount":"$25.00","context":"HIMS closing price on July 29, 2026"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-25T18:10:50.447Z","global_importance":18,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap retail-favorite","eventGravity":"law-firm-solicitation","issuerAuthored":false,"retailFavoriteBoost":true}},"durationMs":6214,"modelName":"glm-5.3-flashx"}}